Clopidogrel Sulfate Pharma Grade API is released as clopidogrel hydrogen sulfate, C₁₆H₁₆ClNO₂S·H₂SO₄, CAS 120202-66-6, with molar mass 419.90 g mol⁻¹. The material is specified against current USP/NF Clopidogrel Bisulfate and Ph.Eur. Clopidogrel Hydrogen Sulfate monographs. Because no universal commercial model code is applied, the API is identified by monograph name, manufacturer lot code, polymorphic form, and particle-size grade. The sulfate salt is intended for oral solid-dose processing—tablet, capsule, and granule—and can be qualified for sterile injectable preparation when additional bioburden, endotoxin, and particulate controls are applied. The molecule is a chiral thienopyridine prodrug; the active S-enantiomer is controlled against the R-enantiomer by chiral HPLC. Lot release data include assay, related substances, residual solvents, elemental impurities, water content, polymorph identity, particle-size distribution, and bulk density. For dose calculation, a 75 mg clopidogrel base equivalent corresponds to 97.9 mg of clopidogrel hydrogen sulfate, based on molecular masses of 321.82 g mol⁻¹ for the free base and 419.90 g mol⁻¹ for the sulfate salt. Batch records must specify salt correction because labeled tablet strength is expressed as base equivalent. Tablet and capsule grades are normally crystalline Form II, selected over Form I because of reproducible solid-state stability under ICH Q1A conditions. X-ray powder diffraction patterns are compared with a certified reference standard; a typical diffractometer configuration uses CuKα radiation at 40 kV and 40 mA, step size 0.02° 2θ, per Ph.Eur. 2.9.33. Differential scanning calorimetry is used to confirm the absence of amorphous domains and solvates. Published data for this exact polymorphic configuration is limited beyond the current monograph identification tests, but the polymorphic ratio is commonly controlled so that Form I content does not exceed the limit established in the approved drug master file. Particle-size control for direct compression is reported by laser diffraction according to ISO 13320:2020. A typical oral solid grade is controlled with D90 not more than 100 µm, D50 in the 10–40 µm range, and D10 not less than 2 µm to limit segregation and improve die filling. Micronized grades with D90 ≤ 20 µm may be used for dissolution-limited formulations, but the higher surface area increases electrostatic charging, cohesive flow, and punch sticking. Bulk and tapped densities are reported per USP 616; batch-to-batch variability in these values should be monitored because changes in particle habit alter capsule fill weight and tablet weight uniformity.

How Does Polymorphic Identity Interact With Direct Compression and Dissolution?

Clopidogrel bisulfate exhibits pH-dependent aqueous solubility and is sensitive to alkaline hydrolysis. Wet granulation should maintain granulation fluid pH below 4.0 and drying temperature below 50 °C because the methyl ester group can hydrolyze under alkaline conditions. Use of povidone binder at 3–5% w/w in low-shear granulation produces granules with acceptable hardness; however, the dried granules should not be milled in a high-energy mill after drying because local frictional heating can induce amorphous conversion. Incompatibility with strongly alkaline disintegrants or effervescent components should be avoided. Magnesium stearate at 0.5–1.0% w/w is generally acceptable when blending time is restricted to 3–5 min; extended high-shear blending retards dissolution in acidic media under USP 711 Apparatus II conditions. Dissolution testing for oral tablet batches uses USP 711 Apparatus II at 37 °C ± 0.5 °C, with paddle speed and medium selected according to the approved regulatory method. Formulation development batches should be evaluated in acidic media because clopidogrel bisulfate release is pH-dependent. Tablet compression requires monitoring ejection force and punch film. Chromium nitride-coated tooling reduces sticking; a 10-station instrumented rotary press operating at 80–120 rpm and compression force 5–15 kN is suitable for development-scale work. Hardness and friability are tested per USP 1216 and USP 1217. Capsule filling may be better served by dry granulation than direct compression when the API is highly charged. Roller compaction with ribbed rolls at 20–40 kN/cm and screen size 0.8–1.2 mm can produce granules with acceptable flow for automatic encapsulation. Processing humidity should be maintained below 40% RH to prevent sticking; published data for this exact configuration is limited, so each manufacturer should verify ribbon density and granule friability before scale-up.

Residual Solvent, Chiral Purity, and Elemental Impurity Release Architecture

Release testing is performed against a certificate of analysis referencing ICH Q3A, Q3C, and Q3D guidance together with current pharmacopoeial general chapters. The following matrix summarizes core specification areas; limits are representative and must be confirmed against the current monograph and approved filing.

Specification Area	Method	Typical Criterion
Appearance	Visual inspection	White to almost white crystalline powder
Assay on dried basis	HPLC per USP <621>	98.0–102.0%
Chiral purity	Chiral HPLC	S-enantiomer ≥99.0%; R-enantiomer ≤1.0%
Total related substances	HPLC	≤0.5%; unspecified impurities ≤0.10%
Water content	Karl Fischer USP <921>	≤0.50%
Residual solvents	GC-HS per USP <467> / Ph.Eur. 2.4.24	ICH Q3C class-specific limits
Elemental impurities	ICP-MS per USP <232>/<233>	ICH Q3D daily-dose and route limits
Polymorph identity	XRPD Ph.Eur. 2.9.33	Crystalline Form II
Particle size	Laser diffraction ISO 13320:2020	D90 ≤100 µm or micronized grade
Bacterial endotoxin, injectable grade	LAL USP <85>	Calculated from dose and route

Injectable grade material is not sterilized by default. It is released with bioburden and endotoxin data so the finished-product manufacturer can design aseptic processing or terminal sterilization. Because clopidogrel bisulfate hydrolyzes in neutral and alkaline solution, injectable compounding should use an acidic vehicle, and final pH is typically below 3.5 unless a buffering or complexation strategy is validated. Particulate matter in the finished injection must meet USP 788; pH and osmolality are controlled by USP 791 and USP 785. Forced degradation at 40 °C/75% RH and in oxidative media should be used to define maximum hold times. Published data for injectable formulations of clopidogrel bisulfate is limited; formulation development should include compatibility screening with Water for Injection, dextrose, and sodium chloride vehicles.

When Injectable Formulations Require Endotoxin and Particulate Control

For sterile injectable dosage forms, the API lot must meet additional microbiological quality attributes. The bacterial endotoxin limit is derived from the maximum bolus dose and route of administration as described in USP 85; if the API is processed into a terminally sterilized injection, the drug substance bioburden should be controlled so that sterilization load does not exceed the validated lethal rate. Filtration of a solution of clopidogrel bisulfate through 0.22 µm filters requires prior compatibility testing because low pH and co-solvent content can affect filter integrity and extractables. For aseptic processing, the filling line should be maintained in an ISO 5 environment with established media-fill performance. The API should not be exposed to open processing at relative humidity above 60% because moisture uptake promotes hydrolysis and particle agglomeration. Thermal stability of the sulfate salt in solution is limited. Terminal sterilization cycles using 121 °C for 15 min may generate degradation products unless the pH is kept below 3.0 and oxygen is excluded by nitrogen sparging. The formulation scientist should quantify clopidogrel carboxylic acid and the oxidized thiophene derivative as degradation markers. Published data for this specific injectable configuration is limited; each manufacturer should generate degradation profiles using a stability-indicating HPLC method.

A Comparison With Clopidogrel Free Base, Besylate, and Non-Thienopyridine P2Y12 Agents

Clopidogrel bisulfate differs from clopidogrel free base in aqueous solubility, handling, and solid-state stability. The free base is an intermediate with low water solubility and is not used directly in oral solid-dose formulations. Clopidogrel besylate is an alternative salt with different counterion, molar mass, crystallinity, and dissolution characteristics; it is not automatically interchangeable with the sulfate salt in a validated formulation. Prasugrel requires cytochrome P450 bioactivation and is supplied as a different salt; ticagrelor is a direct-acting P2Y12 receptor antagonist and does not share the thienopyridine activation pathway.

Material	Class	Salt/Form	CAS	Key API Difference
Clopidogrel bisulfate	Thienopyridine prodrug	Hydrogen sulfate, crystalline Form II	120202-66-6	Low-pH salt; oral solid and injectable-grade qualification
Clopidogrel free base	Thienopyridine prodrug	Free base	113665-84-2	Low aqueous solubility; process intermediate
Clopidogrel besylate	Thienopyridine prodrug	Besylate salt	Manufacturer-specific lot documentation	Different counterion and dissolution/stability profile
Prasugrel	Thienopyridine prodrug	Free base API	150322-43-3	Requires CYP activation; more rapid onset
Ticagrelor	Triazolopyrimidine P2Y12 antagonist	Crystalline free acid	274693-27-5	Direct-acting; no hepatic bioactivation

For oral solid processing, the sulfate salt is selected over the free base because salt formation increases aqueous wetting and bioavailability. The sulfate salt also provides counterion-derived pH in the diffusion layer, but this can accelerate acid-sensitive excipient degradation; film-coated tablets should use moisture-barrier coatings such as polyvinyl alcohol-based film coats rather than high-dextrose aqueous coatings. Direct compression with lactose monohydrate and microcrystalline cellulose is feasible when the API particle size is controlled; however, high-shear blending should be minimized to avoid segregation of dense sulfate particles from lower-density excipients. Storage and handling of clopidogrel sulfate require humidity-controlled dispensing at 15–25 °C and protection from light. Open containers should be reclosed under nitrogen or dry air because oxidative degradation produces sulfoxide-related impurities. The API is incompatible with strong oxidizing agents and should not be combined with amine-functional excipients at high pH. Contact surfaces should be 316L stainless steel or fluoropolymer-lined; published data for specific metal contact is limited, but copper and mild steel are not recommended for acidic processing due to potential metal contamination. If the API is sieved before use, the sieve should be grounded to prevent electrostatic losses and the product should be discharged through a 1.0 mm screen to avoid lump formation. Stability studies are conducted according to ICH Q1A(R2) long-term conditions of 25 °C ± 2 °C / 60% RH ± 5% RH and accelerated 40 °C ± 2 °C / 75% RH ± 5% RH. The API should not be stored above 30 °C for longer than transport excursions; short-term exposure is acceptable only when supported by open-container stability data. The manufacturer should also provide forced degradation data in acid, base, peroxide, heat, and light to support the stability-indicating capability of the analytical method. Process validation for tablet manufacturing should include at least three consecutive lots demonstrating assay, impurity profile, polymorphic form, and dissolution consistency in the intended formulation. A rotary tablet press with 10 stations at 80–120 rpm and compression force 5–15 kN can be used for development; tablet hardness and friability are tested per USP 1216 and USP 1217. Capsule fill weight uniformity is monitored per USP 905. Injectable manufacturing requires aseptic filling in an ISO 5 environment with terminal filtration through 0.22 µm filters after compatibility screening. Cleaning validation requires swab and rinse sampling with acceptance limits derived from health-based exposure limits; residual clopidogrel should be quantified by a validated LC-MS method.